Figure 2.
Expression profile of PD-L1+/− TAMs from patients with TNBC revealed by published scRNA-seq data
(A) Published (Pal et al.27) scRNA-seq transcriptomic clustering of TAMs (n = 4,484 cells) from untreated primary TNBC breast tumors shown as a UMAP.
(B) Mutually exclusive expression of PD-L1 and SIGLEC15 in TAMs.
(C) Dichotomization of TAM clusters into PD-L1+/hi and PD-L1–/lo subpopulations.
(D) PD-L1 expression of PD-L1+/hi and PD-L1–/lo subpopulations.
(E) Volcano plot showing differentially expressed genes (DEGs) between PD-L1+/hi vs. PD-L1−/lo TAMs.
(F) Expression distribution of selected genes involved in maturation, pro-inflammatory, anti-inflammatory, and pro-tumor between PD-L1+/hi and PD-L1–/lo TAMs.
(G) Published (Bassez et al.28) scRNA-seq transcriptomic clustering and dichotomization of TAMs (n = 12,952 cells) from patients with TNBC treated with neoadjuvant anti-PD1 immunotherapy into PD-L1+/hi and PD-L1–/lo subpopulations.
(H) PD-L1 expression of PD-L1+/hi and PD-L1–/lo subpopulations. ∗∗∗∗p < 0.0001. Wilcoxon rank-sum test.
(I) TAMs were annotated based on whether patients exhibited clonal expansion of intratumoral PD1+ T cells after the anti-PD1 treatment as expanded or non-expanded.
(J) The percentages of PD-L1+/hi TAMs were compared between tumors with anti-PD1-induced expanded vs. non-expanded clonal PD1+ T cells. ∗∗p < 0.01. Mann-Whitney test.